Hemorrhage in Posterior Reversible Encephalopathy Syndrome: Imaging and Clinical Features
AJNR 30:1371-1379, Hefzy,H.M.,et al, 2009
Expansion of the Time Window for Treatment of Acute Ischemic Stroke with Intravenous Tissue Plasminogen Activator: A Science Advisory from the American Heart Association/American Stroke Association
Stroke 40:2945-2948, del Zoppo,G.J.,et al, 2009
MR Mismatch Is Useful for Patient Selection for Thrombolysis: Yes
Stroke 40:2906-2907,2910, Fiebach,J.B. &Schellinger,P.D., 2009
Dabigatran Versus Warfarin in Patients with Atrial Fibrillation
NEJM 361:1139-1151, 1200, Connolly,S.,et al, 2009
Brainstem Lesions in Diffusion Sequences of MRI Can be Reversible After Arterial Recanalization
Neurol 73:813-815, Vilas,D., 2009
Outcome of Symptomatic Intracranial Atherosclerotic Disease
Stroke 40:2983-2987, Samaniego,E.,et al, 2009
Intracranial Atherosclerotic Disease: An Update
Ann Neurol 66:730-738, Qureshi,A.,et al, 2009
Cerebral Microbleed Preceding Symptomatic Intracerebral Hemorrhage in a Stroke-Free Person
Neurol 72:763-765, Vernooij,M.W.,et al, 2009
Thrombolytic Therapy for Patients Who Wake-Up With Stroke
Stroke 40:827-832, Barreto,A.D.,et al, 2009
Thrombolysis in Childhood Stroke: Report of 2 Cases and Review of the Literature
Stroke 40:801-807, Arnold,M.,et al, 2009
Disappearing Hyperdense Middle Cerebral Artery Sign in Ischaemic Stroke Patients Treated with Intravenous Thrombolysis: Clinical Course and Prognostic Significance
JNNP 80:273-278,248, Kharitonova,T.,et al, 2009
Moyamoya Disease and Moyamoya Syndrome
NEJM 360:1226-1237, Scott,R.M. &Smith,E.R., 2009
The Ethics of Thrombolytic Trials Beyond 3 (or 4.5) Hours: Randomized Controlled Trials Are Required to Change Clinical Practice
Stroke 40:1545, Donnan,G.A. &Davis,S.M., 2009
Effect of Age on Stroke Prevention Therapy in Patients with Atrial Fibrillation: The Atrial Fibrillation Investigators
Stroke 40:1410-1416, van Walraven,C.,et al, 2009
Effect of Clopidogrel Added to Aspirin in Patients with Atrial Fibrillation
NEJM 360:2066-2078,2127, The ACTIVE Investigators, 2009
Cost-Effectiveness of Patient Selection Using Penumbral-Based MRI for Intravenous Thrombolysis
Stroke 40:1710-1720, Earnshaw,S.R.,et al, 2009
Identifying Patients at High Risk for Poor Outcomes After Intra-Arterial Therapy for Acute Ischemic Stroke
Stroke 40:1780-1785, Hallevi,H.,et al, 2009
Does the Combination of Warfarin and Aspirin Have a Place in Secondary Stroke Prevention? No
Stroke 40:1944-1945,1946, Fisher,M., 2009
Does the Combination of Warfarin and Aspirin Have a Place in Secondary Stroke Prevention? Yes
Stroke 40:1942-1943,1946, Furlan,A.J., 2009
Prior Antiplatelet Use Dose Not Affect Hemorrhage Growth or Outcome After ICH
Neurol 72:1397-1402,1376, Sansing,L.H.,et al, 2009
Telemedicine Versus Telephone for Remote Emergency Stroke Consultations: A Critically Appraised Topic
The Neurologist 15:163-166, Capampngan,D.J.,et al, 2009
Intracerebral Haemorrhage
Lancet 373:1632-1644, Qureshi,A.I.,et al, 2009
Thrombolysis in Young Adults with Ischemic Stroke
Stroke 40:2085-2091, Putaala,J.,et al, 2009
Treatment of Atherosclerotic Intracranial Arterial Stenosis
Stroke 40:2257-2261, Turan,T.N.,et al, 2009
4.5 Hours: The New Time Window for Tissue Plasminogen Activator in Stroke
Stroke 40:2266-2267, Davis,S.M. &Donnan,G.A., 2009
Cerebral Microbleeds Are a Risk Factor for Warfarin-Related Intracerebral Hemorrhage
Neurol 72:171-176, Lee,S.-H.,et al, 2009
Use of MRI to Estimate the Therapeutic Window in Acute Stroke: Is Perfusion-Weighted Imaging/Diffusion-Weighted Imaging Mismatch an EPITHET for Salvageable Ischemic Brain Tissue?
Stroke 40:333-335, Toth,G. &Albers,G.W., 2009
Potentially Preventable Strokes in High-Risk Patients with Atrial Fibrillation Who Are Not Adequately Anticoagulated
Stroke 40:235-240,5, Gladstone,D.J.,et al, 2009
Recurrent Cerebral Ischemia in Medically Treated Patent Foramen Ovale: A Meta-Analysis
Neurol 73:89-97,84, Almekhlafi,M.A.,et al, 2009
Intraarterial Thrombolysis Within the First Three Hours After Acute Ischemic Stroke in Selected Patients
Stroke 40:2611-2612,2615, Moonis,M., 2009
Is Intraarterial tPA Within 3 Hours the Treatment of Choice for Selected Stroke Patients? No
Stroke 40:2613-2614,2615, Lindley,R.I., 2009
Number Needed to Treat to Benefit and to Harm for Intravenous Tissue Plasminogen Activator Therapy in the 3- to 4.5-Hour Window: Joint Outcome Table Analysis of the ECASS 3 Trial
Stroke 40:2433-2437,2295, Saver,J.L.,et al, 2009
Efficacy and Safety of Tissue Plasminogen Activator 3 to 4.5 Hours After Acute Ischemic Stroke: A Metaanalysis
Stroke 40:2438-2441, Lansberg,M.G.,et al, 2009
Stroke Therapy Academic Industry Roundtable (STAIR) Recommendations for Extended Window Acute Stroke Therapy Trials
Stroke 40:2594-2600, Saver,J.L.,et al, 2009
Use of Antithrombotic Drugs and the Presence of Cerebral Microbleeds: The Rotterdam Scan Study
Arch Neurol 66:714-720,691, Vernooij,M.W.,et al, 2009
Percutaneous Closure of the Left Atrial Appendage Versus Warfarin Therapy for Prevention of Stroke in Patients with Atrial Fibrillation: A Randomised Non-Inferiority Trial
Lancet 374:534-542,504, Holmes,D.R.,et al, 2009
Antithrombotic Management of Patients with Prosthetic Heart Valves: Current Evidence and Future Trends
Lancet 374:565-576, Sun,J.C.J.,et al, 2009
Who Is Ineligible for Warfarin in Atrial Fibrillation?
Lancet 374:510-511, Verheugt,F.W.A., 2009
Transcranial Ultrasound in Clinical Sonothrombolysis (TUCSON) Trial
Ann Neurol 66:28-38, Molina,C.A.,et al, 2009
Point-of-Care International Normalized Ratio Testing Accelerates Thrombolysis in Patients With Acute Ischemic Stroke Using Oral Anticoagulants
Stroke 40:3547-3551, Rizos,T.,et al, 2009
Medial Medullary Infarction: Clinical, Imaging, and Outcome Study in 86 Consecutive Patients
Stroke 40:3221-3225, Kim,J. &Han,Y., 2009
Intraventricular Fibrinolysis and Lumbar Drainage for Ventricular Hemorrhage
Stroke 40:3275-3280, Staykov,D.,et al, 2009
Admission International Normalized Ratio and Acute Infarct Volume in Ischemic Stroke
Ann Neurol 64:499-506, Ay,H.,et al, 2008
Treating Patients with Wake-Up Stroke: The Experience of the AbESTT-II Trial
Stroke 39:3277-3282, Adams,H.P.,et al, 2008
Managing the Anticoagulated Patient with Atrial Fibrillation at High Risk of Stroke Who Needs Coronary Intervention
BMJ 337:1110-1111, Lip,G.Y.H., 2008
Review of Tissue Plasminogen Activator, Ischemic Stroke, and Potential Legal Issues
Arch Neurol 65:1429-1433, Liang,B.A.,et al, 2008
Anticoagulation Prior to and After Restoration of Sinus
UpToDate, December, Manning,W.J. &Arnsdorf,W.F., 2008
Barriers to the Use of Anticoagulation for Nonvalvular Atrial Fibrillation: A Representative Survey of Australian Family Physicians
Stroke 39:227-230,7, Gattellari,M.,et al, 2008
Rapid Assessment of Perfusion-Diffusion Mismatch
Stroke 39:75-81, Butcher,K.,et al, 2008
Emergency Administration of Abciximab for Treatment of Patients With Acute Ischemic Stoke: Results of an International Phase III Trial: Abciximab in Emergency Treatment of Stroke Trial (AbESTT-II)
Stroke 39:89-99, Adams,H.P.,Jr.,et al, 2008